Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace HoldingsMEDP +1.96%96 Forward Rate of Return (Yacktman) % is 22.84% as of Jun. 2026, which is 1% above its 10-year median of 22.66. GuruFocus rates MEDP with a GF Score™ of 96/100 and a GF Value™ of $536.14 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 93 Medical Diagnostics & Research companies, Medpace Holdings ranks better than 88.17% on this metric.
Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. Medpace Holdings's forward rate of return for was 22.84%.
The historical rank and industry rank for Medpace Holdings's Forward Rate of Return (Yacktman) % or its related term are showing as below:
MEDP'
s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 19.66 Med: 22.66 Max: 24.48
Current: 22.56
During the past 13 years, Medpace Holdings's highest Forward Rate of Return was 24.48. The lowest was 19.66. And the median was 22.66.
MEDP's Forward Rate of Return (Yacktman) % is ranked better than 88.17% of 93
companies
in the Medical Diagnostics & Research industry
Industry Median: 5.84
vs MEDP: 22.56
Unlike the Earnings Yield %, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Medpace Holdings (NAS:MEDP) Forward Rate of Return (Yacktman) % Explanation
Unlike the Earnings Yield, the Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
For the growth part of the Forward Rate of Return calculation, GuruFocus uses the 5-year average growth rate of EBITDA per share as the growth rate, and the growth rate is always capped at 20%. For the Free Cash Flow we use per share data averaged over five years. The reason we use five years is to make it comparable to the growth rate.
Be Aware
In the Forward Rate of Return calculation, the growth rate is added directly to today's free cash flow yield. Therefore the calculation is reliable only if the company can grow at the same rate in the future as it did in the past. Investors should pay close attention to this when researching growth stocks. A more accurate measurement for return is Return on Capital.
Medpace Holdings Forward Rate of Return (Yacktman) % Related Terms
Medpace Holdings Forward Rate of Return (Yacktman) % Historical Data
* Premium members only.
The historical data trend for Medpace Holdings's Forward Rate of Return (Yacktman) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medpace Holdings Forward Rate of Return (Yacktman) % Chart
MEDP vs RVTY, CRL, ICLR: Forward Rate of Return (Yacktman) % Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's Forward Rate of Return (Yacktman) %, along with its competitors' market caps and Forward Rate of Return (Yacktman) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings Forward Rate of Return (Yacktman) % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's Forward Rate of Return (Yacktman) % distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's Forward Rate of Return (Yacktman) % falls into.
Medpace Holdings Forward Rate of Return (Yacktman) % Calculation
Forward Rate of Return is a concept that Don Yacktman uses in his investment approach. Yacktman explained the forward rate of return concept in detail in his interview with GuruFocus. Yacktman defines forward rate of return as the normalized free cash flow yield plus real growth plus inflation. He said in the interview (March 2012, when the S&P 500 was at about 1400):
If the business is stable, this calculation is fairly straightforward. For instance, on the S&P 500 we would normalize earnings. We would then calculate what percentage of those earnings are not reinvested in the underlying businesses and are therefore free. Historically, for the S&P 500, this has been just under 50% of earnings. Currently, we expect the S&P to earn about 70 on a normalized basis, a number which is far below reported earnings due to our adjusting for record high profit margins. $70 X ½ / 1400 gives you a normalized free cash flow yield of approximately 2.5%.
The historical real growth rate of the S&P 500 (companies) is about 1.5%. Assuming an inflation rate of 2.5%, the forward rate of return on an investment in the S&P 500 is about 6.5% today (2.5% free cash flow yield plus 1.5% real growth plus 2.5% inflation).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Forward Rate of Return (Yacktman) % of 22.84% mean?
Medpace Holdings (MEDP) has a Forward Rate of Return (Yacktman) % of 22.84% as of Jun. 2026. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Medpace Holdings and its competitors. This is near median its historical median of 22.66. Over the past decade, Medpace Holdings' Forward Rate of Return (Yacktman) % has ranged from 19.66 to 24.48. According to the industry distribution chart, Medpace Holdings ranks #11 out of 93 companies in the Medical Diagnostics & Research industry, placing it in the top 11.8%.
Is Medpace Holdings' Forward Rate of Return (Yacktman) % too high?
Medpace Holdings' current Forward Rate of Return (Yacktman) % of 22.84% is near median its 10-year median of 22.66. Over the past 10 years, this metric has ranged from a low of 19.66 to a high of 24.48. The Medical Diagnostics & Research industry median Forward Rate of Return (Yacktman) % is 5.84. Medpace Holdings' value of 22.84% is 291.1% above this industry median. Based on the distribution chart, Medpace Holdings ranks #11 out of 93 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Medpace Holdings has a GF Score™ of 96/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' Forward Rate of Return (Yacktman) % compare to RVTY and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Medpace Holdings ranks #11 out of 93 companies for Forward Rate of Return (Yacktman) %. This places Medpace Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Forward Rate of Return (Yacktman) % is 5.84. Medpace Holdings' value of 22.84% is 291.1% above this benchmark. Historically, Medpace Holdings' own Forward Rate of Return (Yacktman) % has ranged from 19.66 to 24.48 over the past decade. While the company's 10-year median is 22.66 vs. the industry median of 5.84, Medpace Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Rate of Return (Yacktman) % for a Medical Diagnostics & Research company?
The median Forward Rate of Return (Yacktman) % among Medical Diagnostics & Research companies is 5.84, based on 93 companies in the industry. Companies in the top quartile (top 25%) have a Forward Rate of Return (Yacktman) % significantly above this median, while those in the bottom quartile fall well below. However, Forward Rate of Return (Yacktman) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medpace Holdings's current Forward Rate of Return (Yacktman) % of 22.84% is 291.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Rate of Return (Yacktman) % mean?
A high Forward Rate of Return (Yacktman) % can signal that a stock is expensive relative to its fundamentals. Yacktman's forward rate of return equals the sum of normalized free-cash-flow yield plus earnings growth. View historical data on Medpace Holdings and its competitors. For the Medical Diagnostics & Research industry, the median Forward Rate of Return (Yacktman) % is 5.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medpace Holdings's current Forward Rate of Return (Yacktman) % is 22.84%, which is near median its own 10-year median of 22.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (MEDP) is currently considered Modestly Overvalued. The stock's GF Value™ is $536.14, compared to a current price of $624.21 — trading 16.4% above its estimated fair value. The current Forward Rate of Return (Yacktman) % is 22.84%, which is near median its 10-year median of 22.66 and 291.1% above the Medical Diagnostics & Research industry median of 5.84. Medpace Holdings' overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Rate of Return (Yacktman) % calculated?
Forward Rate of Return (Yacktman) % is calculated from a company's financial statements. For Medpace Holdings (MEDP), the current Forward Rate of Return (Yacktman) % is 22.84% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (MEDP) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of $624.21 is trading 16.4% above its estimated GF Value™ of $536.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for MEDP:
Forward Rate of Return (Yacktman) %: 22.84% (near median its 10-year median of 22.66)
GF Value™: $536.14 vs. price of $624.21 (16.4% above fair value)
Industry Position: 291.1% above the Medical Diagnostics & Research median (#11 of 93)
No single metric tells the full story. See the MEDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
96GF Score
Get the complete analysis for MEDP
Forward Rate of Return (Yacktman) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEDP has been successfully added to your 
